Broad Genetic Testing for NSCLC May Not Improve Survival

Compared with routine genetic testing, no improvement seen in unadjusted mortality rate
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pathology, Pulmonology, Journal, Source Type: news

Related Links:

This study retrospectively assessed the clinical and biological parameters of 223 patients with advanced NSCLC. Univariate and multivariate analyses of overall survival (OS) and progression-free survival (PFS) for the parameters and the prognostic score were assessed. RESULTS Performance status (PS) score=1, smoking history, fibrinogenemia, thrombocytosis, increased lactate dehydrogenase (LDH) level, and anemia were independent predictors of poor prognosis in the univariate analysis of OS and were assessed in multivariate analysis. There was a significant difference in PS=1 (HR=2.134, p
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Publication date: Available online 17 November 2018Source: Seminars in Cancer BiologyAuthor(s): Verena Schildgen, Oliver SchildgenAbstractDriver mutations are considered to be responsible for the majority of cancers and several of those mutations provide targets in order to set up personalized therapies. So far the generally accepted opinion had been that driver mutations occur as stand-alone factors, but novel sequencing technologies induced an essential rethink. Next generation sequencing approaches have shown that double, triple or multiple concurrent mutations could occur within the same tumour and may by interaction i...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 17 November 2018Source: The Annals of Thoracic SurgeryAuthor(s): Masaya Tamura, Isao Matsumoto, Yusuke Tanaka, Daisuke Saito, Shuhei Yoshida, Seiichi Kakegawa, Tomoyasu Kumano, Yosuke Shimizu, Hiroyasu Tamamura, Tsuyoshi Takanaka, Hirofumi TakemuraAbstractBackgroundThe aim of this study was to compare outcomes of primary treatment with stereotactic body radiation therapy (SBRT) versus sublobar resection (SLR) for clinical stage I non-small cell lung cancer (NSCLC) in patients with medical comorbidities.MethodsConsecutive patients who underwent SBRT (n=106) or SLR (wedge resection: n=100 a...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Authors: Adrianzen Herrera D, Ashai N, Perez-Soler R, Cheng H Abstract INTRODUCTION: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor, has demonstrated clinical efficacy in the treatment of advanced non-small cell lung cancer (NSCLC) either as monotherapy or in combination. Nab-paclitaxel was developed to reduce the toxicities associated with solvent-bound paclitaxel (sb-paclitaxel). Areas covered: This review first focuses on the clinical trials evaluating the efficacy and tolerability of nab-paclitaxel in NSCLC at different settings. The approval of nab-paclitaxel in combination wit...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Authors: Abstract The interaction between pituitary hormones, GH - PRL, and Growth Factors, GF, plays a fundamental role in the physiological and neoplastic mechanisms of growth, the latter using these factors to a much greater extent compared to the former, with a direct dose-dependent effect on the speed of local or metastatic expansion. In hormone-dependent tumours, the respective male and female sex hormones interact with GH - PRL - GF to sustain the expansion of the tumour. We carried out a review of the literature on the relationship between the expression of GH and GHR in tumour tissues compared to healthy ...
Source: Neuroendocrinology Letters - Category: Endocrinology Tags: Neuro Endocrinol Lett Source Type: research
Authors: Abstract Neurofibromatosis type 1 (NF1, von Recklinghausen disease) is inherited in autosomal dominant way genetic disorder, with an incidence at birth 1:3000. It is one of the most common congenital disorders. It is characterized by café-au-lait spots, neurofibromas, and less common MPTST and gliomas of the optic nerve. It is caused by germline mutations of the NF1 gene, which acts as tumor suppressor. Inactivation of the gene leads to increased activation of the kinase pathways, and in consequence, uncontrolled proliferation of cells. The disease predisposes to the development of both benign and ...
Source: Neuroendocrinology Letters - Category: Endocrinology Tags: Neuro Endocrinol Lett Source Type: research
CONCLUSIONS The results of this research indicate that the metastases of non-small cell lung cancer can predict RET rearrangement of the primary tumor tissue in the majority of cases. Testing for RET rearrangement in metastases can be used as an alternative to testing of primary tumor tissue if it is inaccessible. PMID: 30429449 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Non-small cell lung cancer (NSCLC) represents more than about 80% of the lung cancer. The early stages of NSCLC can be treated with complete resection with a good prognosis. However, most cases are detected at...
Source: BMC Medical Genomics - Category: Genetics & Stem Cells Authors: Tags: Research Source Type: research
Non-small cell lung cancer (NSCLC) involving mediastinal lymph nodes without an identifiable primary tumor (i.e. occult primary NSCLC or OP-NSCLC) is an uncommon presentation and rare diagnosis. To date there are fewer than 100 cases reported in the literature, most of which are single patient case reports [1 –7]. OP-NSCLC is defined as the absence of an identifiable primary lung tumor, in the setting of mediastinal lymph node pathology consistent with a tumor arising from the lung. Therefore, a detailed and thorough staging workup is necessary to rule out metastatic involvement from a non-thoracic pri mary site.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
The authors regret that we mistook the PD-L1 immunohistochemistry data in Table 1 for that of circulating tumor cell.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Corrigendum Source Type: research
More News: Cancer & Oncology | Genetics | Non-Small Cell Lung Cancer | Pathology